Pharma industry calls for broad-based cooperation to fight on-line sales of counterfeit medicines

24 July 2012

The global pharmaceutical industry unveiled recommendations this week to tackle the growing public health threat of counterfeit or fake medicines. The industry’s call for increased public awareness and crackdown on makers of the unsafe products comes as a group of private US companies – including Google and Go Daddy - launches the Center for Safe Internet Pharmacies (CSIP) initiative to target illegal Internet pharmacies.

The four research-based associations – the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), and Japanese Pharmaceutical Manufacturers Association (JPMA) – support broad-based initiatives like the CSIP as important steps in the fight against counterfeits.

Scale of the problem

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Biotechnology